Risk of Interstitial Lung Disease in COVID-19 Patients with Autoimmune Diseases Treated with Antiviral Agents

This retrospective cohort study utilizing TriNetX data found no statistically significant difference in the risk of developing interstitial lung disease between COVID-19 patients with autoimmune diseases treated with Paxlovid versus those treated with Molnupiravir, suggesting both antivirals are safe options regarding this specific complication for this vulnerable population.

The Gist

🦠 The Big Question: Are the COVID Pills Safe for Autoimmune Patients?

Imagine your body is a fortress. For most people, the gates are open and the guards (your immune system) are ready to fight off invaders like the coronavirus.

But for people with autoimmune diseases (like rheumatoid arthritis or lupus), the guards are a bit confused. They sometimes attack the fortress itself (the body's own tissues). To stop this, doctors often give these patients "peacekeepers" (immunosuppressants) to calm the guards down.

When the pandemic hit, two new "anti-virus missiles" were launched to fight the coronavirus: Paxlovid and Molnupiravir.

The Worry:
Doctors were nervous. They knew these missiles were great for normal fortresses, but what about the ones with confused guards? Specifically, they were worried about a specific side effect: Interstitial Lung Disease (ILD). Think of ILD as the lung's "scar tissue" or "rusting." If the lungs get too rusty, they can't breathe well. The fear was that these pills might accidentally cause the lungs to rust faster in people who already have autoimmune issues.

🔬 The Experiment: A Digital Matchmaking Service

The researchers didn't just guess; they ran a massive digital experiment using a giant database called TriNetX (think of it as a super-powered library containing the medical records of millions of Americans).

1. The Crowd: They found over 18,000 patients who had both COVID-19 and an autoimmune disease.
2. The Split: They divided them into two teams:
   • Team Paxlovid: Took the nirmatrelvir-ritonavir pill.
   • Team Molnupiravir: Took the molnupiravir pill.
3. The Matchmaker (Propensity Score Matching): This is the most important part. Before comparing the teams, the researchers acted like a strict matchmaker. They paired every person on Team Paxlovid with a person on Team Molnupiravir who was almost identical in every way: same age, same gender, same race, same health problems, and even the same medications they were taking for their autoimmune disease.
   • Analogy: Imagine a boxing match. You wouldn't let a 100-pound rookie fight a 250-pound champion. The researchers made sure both fighters were the exact same weight and skill level before the bell rang. This ensures that if one team wins (or loses), it's because of the pills, not because one team was weaker to begin with.

📊 The Results: A Dead Heat

After the match, the researchers looked at the scoreboard to see who developed lung scarring (ILD).

• Team Paxlovid: 54 people developed lung issues.
• Team Molnupiravir: 79 people developed lung issues.

The Verdict:
Statistically, this difference wasn't big enough to say one pill was "safer" than the other. The numbers were close enough that it looked like a tie.

• The Analogy: It's like flipping a coin 18,000 times. If you get 54 heads and 79 tails, you might think the coin is weighted, but in this case, the "coin" (the risk) is actually fair. The study concluded that neither pill caused a significant increase in lung scarring compared to the other.

🌳 Breaking it Down by Groups (Subgroups)

The researchers also checked if the results changed for different types of people, just to be extra sure. They looked at:

• Age: Old vs. Young.
• Gender: Men vs. Women.
• Race: Different ethnic groups.

The Finding: The "tie" held up everywhere. Whether you were 25 or 85, male or female, the risk of lung scarring was roughly the same for both pills.

(Note: There were very few people in some specific groups, like Black patients, so the data there was a bit shaky—like trying to predict the weather with only three clouds—but for the vast majority, the results were clear.)

🏁 The Bottom Line

What does this mean for you?

If you have an autoimmune disease and catch COVID-19, you don't need to panic about choosing between Paxlovid or Molnupiravir based on fear of lung scarring.

• The Good News: Both pills appear to be safe regarding this specific lung risk.
• The Takeaway: Doctors can prescribe either one without worrying that one will suddenly turn your lungs into a brick wall. The choice can be made based on other factors (like drug interactions or availability), not fear of lung damage.

In a nutshell: The study took a huge crowd of confused-guard fortresses, gave them two different virus-fighting tools, and found that neither tool made the fortress walls crumble any faster than the other. You can breathe a little easier knowing both options are on the table.

Technical Summary

1. Problem Statement

• Context: Nirmatrelvir-ritonavir (Paxlovid) and Molnupiravir are primary outpatient antiviral treatments for SARS-CoV-2. While effective for the general population, their safety profiles in patients with pre-existing autoimmune diseases (AID) remain poorly characterized.
• Specific Concern: Patients with AIDs are often immunocompromised and may have underlying lung pathology. There is a specific clinical uncertainty regarding whether these antivirals increase the risk of Interstitial Lung Disease (ILD) exacerbation or new onset, a severe condition involving lung tissue scarring.
• Knowledge Gap: Previous pivotal clinical trials for these antivirals largely excluded or underrepresented immunosuppressed individuals and those with complex autoimmune phenotypes (e.g., Rheumatoid Arthritis with ILD). Consequently, clinicians lack evidence-based guidance on the comparative safety of Paxlovid versus Molnupiravir regarding ILD risk in this high-risk cohort.

2. Methodology

• Study Design: Retrospective cohort study utilizing real-world data.
• Data Source: The US Collaborative Network (TriNetX), covering data from 2020 to 2023.
• Study Population:
  • Initial Pool: 112,376,696 individuals diagnosed with COVID-19.
  • Inclusion Criteria: Patients with a pre-existing diagnosis of autoimmune diseases who received either Paxlovid or Molnupiravir within 5 days of COVID-19 diagnosis.
  • Exclusion Criteria: Patients with a diagnosis of ILD prior to or within 5 days of the initial COVID-19 diagnosis (to ensure incident cases were captured).
• Matching Strategy: To minimize selection bias and confounding, the authors employed 1:1 Propensity Score Matching (PSM).
  • Covariates: Age, sex, race, socioeconomic status (SES), medical utilization, comorbidities (hypertension, diabetes, ischemic heart disease), vaccination status, and specific autoimmune diagnoses.
  • Final Cohort: 9,192 patients in the Paxlovid group matched with 9,192 patients in the Molnupiravir group (Total N = 18,384).
• Primary Outcome: Incidence of new ILD diagnosis post-treatment, defined by ICD-10-CM code J84 and confirmed by radiographic evidence.
• Statistical Analysis:
  • Kaplan-Meier survival analysis.
  • Cox proportional hazards models to calculate Hazard Ratios (HR) and 95% Confidence Intervals (CI).
  • Subgroup analyses stratified by age (<65 vs. ≥65), sex, race, and BMI.
  • Standardized Mean Difference (SMD) used to verify balance between groups post-matching.

3. Key Contributions

• Targeted Population Focus: This is one of the first large-scale studies specifically isolating the risk of ILD in patients with pre-existing autoimmune conditions, a group often excluded from major antiviral trials.
• Comparative Safety: It provides a direct head-to-head comparison of Paxlovid and Molnupiravir regarding respiratory safety in a high-risk demographic, rather than comparing treated vs. untreated groups.
• Robust Statistical Control: The use of rigorous PSM with extensive covariate adjustment (including specific immunosuppressive medications like methotrexate, tocilizumab, and corticosteroids) strengthens the validity of the causal inference in an observational setting.
• Granular Subgroup Analysis: The study breaks down risks by demographic factors (race, age, sex) and BMI, addressing potential disparities in treatment safety.

4. Results

• Primary Outcome (ILD Incidence):
  • Paxlovid Group: 54 cases of ILD out of 9,192 patients.
  • Molnupiravir Group: 79 cases of ILD out of 9,192 patients.
  • Statistical Finding: The Hazard Ratio (HR) was 0.73 (95% CI: 0.52–1.03).
  • Interpretation: The confidence interval includes 1.0, indicating no statistically significant difference in the risk of developing ILD between the two treatment groups.
• Baseline Characteristics: Post-matching, the two groups were well-balanced with SMDs < 0.1 for all covariates, confirming successful matching.
• Subgroup Analysis:
  • Age: HR for <65 was 0.97; HR for ≥65 was 1.03.
  • Sex: HR for females was 1.10; HR for males was 0.81.
  • Race: HR for White patients was 0.92. For Black/African American patients, the HR was 3.74, but the 95% CI was extremely wide (0.74–18.84) due to low event numbers, indicating low statistical power for this specific subgroup rather than a definitive risk increase.
• Secondary Outcomes: No significant differences were observed in post-treatment medical utilization (ambulatory, emergency, or inpatient visits) between the groups.
• Sensitivity Analysis: Adjustments for BMI and vaccination status did not alter the primary findings.

5. Significance and Implications

• Clinical Practice: The findings suggest that healthcare providers can prescribe either Paxlovid or Molnupiravir to patients with autoimmune diseases without a heightened concern for inducing or exacerbating Interstitial Lung Disease. This addresses a critical hesitation in treating this vulnerable population.
• Policy and Guidelines: The results support the inclusion of autoimmune patients in standard antiviral treatment guidelines, potentially reducing treatment disparities.
• Research Direction: The study highlights the need for future prospective research to validate these findings, particularly regarding long-term respiratory outcomes and the interaction between specific immunosuppressive therapies and antiviral mechanisms.
• Limitations Acknowledged: As an observational study, it cannot prove causality and may suffer from residual confounding. Additionally, the study period (2020–2023) predates some newer viral variants, and the wide confidence intervals in minority racial subgroups suggest a need for more diverse data collection.

Conclusion: The study concludes that neither Paxlovid nor Molnupiravir significantly increases the risk of Interstitial Lung Disease in COVID-19 patients with pre-existing autoimmune diseases, supporting the safe use of both agents in this high-risk population.